Stock Region Penny Picks
Stock Region Penny Picks Watchlist: Monday, October 13, 2025.
Stock Region Penny Picks Watchlist: Monday, October 13, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This content is for informational purposes only. You should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in our newsletter constitutes a solicitation, recommendation, endorsement, or offer by Stock Region or any third-party service provider to buy or sell any securities or other financial instruments. All content on this site is information of a general nature and does not address the circumstances of any particular individual or entity. I am not a financial advisor. This is not financial advice.
Good morning, everyone, and welcome to another week in the markets. The coffee is brewing, the charts are up, and we’ve got a couple of tickers on our radar this morning that are making some serious noise before the opening bell.
Let’s dive right into what’s catching my eye.
1. Abeona Therapeutics ($ABEO)
The News: Abeona announced this morning that their ABO-503 Gene Therapy for a rare eye disease was selected by the FDA for its Rare Disease Endpoint Advancement (RDEA) Pilot Program.
Okay, let’s break this down. Anytime you see “FDA” and “Pilot Program” in the same sentence for a biotech company, your ears should perk up. This is a big deal. The FDA is essentially giving Abeona a helping hand, which could streamline the approval process for their gene therapy. This isn’t just a pat on the back; it’s a potential fast track.
For a small-cap biotech like ABEO, news like this is pure rocket fuel. It adds a layer of validation and de-risks the asset in the eyes of many investors. While the path for any drug is long and filled with hurdles, getting this kind of nod from the FDA is a significant positive catalyst. I’m definitely watching this one closely at the open. It has the potential for some serious momentum today.
2. ENDRA Life Sciences ($NDRA)
The News: ENDRA announced an at-the-market private placement of up to $14.4 million to launch a “Digital Asset Treasury Strategy.” They’ve hired a leading crypto asset manager, Arca, to handle it.
Hold on a second. This one is a head-scratcher, and frankly, it feels a bit wild. ENDRA is a medical imaging company, and now they’re suddenly pivoting to a crypto treasury strategy? This feels like a company from 2021 that just woke up from a coma.
On one hand, you could argue they’re trying to be “innovative” with their cash reserves. On the other hand, and this is where I lean, it screams desperation. Why would a medical device company need to get into crypto? It introduces a massive amount of volatility and risk that has absolutely nothing to do with their core business. It makes me question the management’s focus. Are they trying to develop medical technology or are they trying to time the crypto market?
This move seems to inject unnecessary risk into the company. I’ll be watching this, but more out of morbid curiosity than anything else. It could attract some speculative traders, but for me, this is a red flag. It feels like a gimmick to get attention, and I’m not buying it.
Disclaimer: The content provided in this newsletter is for informational and entertainment purposes only. I am not a licensed financial advisor, and the information presented here is not investment advice. All investments involve risk, and you should conduct your own due diligence and consult with a qualified financial professional before making any investment decisions. The opinions expressed are my own and are subject to change without notice.